TOP TEN perturbations for 38795_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38795_s_at
Selected probe(set): 225982_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38795_s_at (225982_at) across 6674 perturbations tested by GENEVESTIGATOR:
male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):2.1428823Number of Samples:5 / 8
| Experimental | male infertility study 1 (juvenile; Ad+) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):1.9218025Number of Samples:2 / 8
| Experimental | male infertility study 1 (juvenile; Ad-) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-1.8730125Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):1.790822Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-1.7581968Number of Samples:4 / 4
| Experimental | R547 study 3 (6h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Relative Expression (log2-ratio):1.7409678Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) |
| CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):-1.5465918Number of Samples:5 / 7
| Experimental | E. coli study 2 |
| Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
| Control | unstimulated, normal monocyte-derived macrophage sample |
| Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-1.4878645Number of Samples:4 / 4
| Experimental | R547 study 1 (6h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.473238Number of Samples:4 / 4
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |
T-helper activation study 1 (340min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):-1.4573708Number of Samples:2 / 2
| Experimental | T-helper activation study 1 (340min) |
| Alloantigen specific helper T-cells were stimulated for 340min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
| Control | unstimulated helper T-cell sample |
| Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
Organism: Homo sapiens
Gene: 38795_s_at
Selected probe(set): 1558215_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38795_s_at (1558215_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
IgA nephropathy study 8 / control glomerulus tissue
Relative Expression (log2-ratio):2.6897326Number of Samples:20 / 20
| Experimental | IgA nephropathy study 8 |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures. | |
| Control | control glomerulus tissue |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):2.528593Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):2.217166Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):-2.1890068Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):1.9591045Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):1.9326153Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal T-cell sample |
| MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.9119358Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):1.8966904Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal T-cell; 20uM) |
| MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-1.882451Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-1.8646908Number of Samples:4 / 8
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |